70,208 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Bought by Two Sigma Investments LP

Two Sigma Investments LP bought a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 70,208 shares of the company's stock, valued at approximately $496,000. Two Sigma Investments LP owned about 0.12% of Health Catalyst as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Legato Capital Management LLC lifted its holdings in shares of Health Catalyst by 3.7% in the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company's stock worth $622,000 after acquiring an additional 3,171 shares during the last quarter. Martin & Co. Inc. TN raised its position in Health Catalyst by 80.0% in the fourth quarter. Martin & Co. Inc. TN now owns 490,998 shares of the company's stock valued at $3,471,000 after purchasing an additional 218,293 shares during the period. Impax Asset Management Group plc lifted its stake in Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock worth $19,442,000 after purchasing an additional 195,525 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Health Catalyst during the fourth quarter worth $2,044,000. Finally, AlphaQuest LLC grew its stake in shares of Health Catalyst by 1,989.8% in the fourth quarter. AlphaQuest LLC now owns 87,395 shares of the company's stock valued at $618,000 after buying an additional 83,213 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Stephens decreased their target price on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 6th. Royal Bank of Canada reduced their price target on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 27th. KeyCorp dropped their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, April 16th. Evercore ISI downgraded shares of Health Catalyst from an "outperform" rating to an "inline" rating in a research note on Wednesday, April 9th. Finally, Citigroup decreased their price target on shares of Health Catalyst from $7.00 to $6.50 and set a "buy" rating for the company in a research report on Friday, April 25th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $8.00.

Health Catalyst Stock Up 3.0%

Health Catalyst stock traded up $0.12 during trading on Thursday, reaching $4.08. The stock had a trading volume of 322,995 shares, compared to its average volume of 603,463. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 52-week low of $3.49 and a 52-week high of $9.24. The stock has a market cap of $283.97 million, a PE ratio of -3.02 and a beta of 1.53. The business has a 50 day moving average price of $3.94 and a 200 day moving average price of $5.30.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.